Your dog was diagnosed with Appendicular Osteosarcoma. Most common primary bone tumour in dogs (~85% of skeletal tumours). Incidence 27× higher than in humans. ~90–95% of dogs have micrometastatic disease at diagnosis. Large and giant breeds overwhelmingly predisposed. Compare 7 treatment options for dogs including Amputation + Adjuvant Carboplatin, Amputation + Adjuvant Doxorubicin, Limb-Sparing Surgery + Adjuvant Chemotherapy — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Appendicular Osteosarcoma
Canine Oncology Treatment Guide
Appendicular Osteosarcoma
Stage I (localised) – III (metastatic)
Mesenchymal
About This Cancer
Osteosarcoma is the most common bone cancer in dogs, arising from bone-forming cells (osteoblasts) that begin to grow and divide uncontrollably. In the appendicular (limb) form, the tumour typically develops near the growth plates of the long bones — most often the radius (near the wrist) or the proximal humerus (shoulder area) in the forelimbs, and the distal femur or proximal tibia (around the knee) in the hind limbs. The disease is strongly associated with large and giant breeds such as Rottweilers, Great Danes, and Irish Wolfhounds. The tumour causes progressive bone destruction and pain, often presenting as worsening lameness. Critically, at the time of diagnosis, the overwhelming majority of dogs (roughly 90–95%) already have microscopic cancer cells that have spread to the lungs, even though these are too small to detect on X-rays. This is why treatment plans address both the primary tumour and this invisible distant disease.
Enneking Staging System (adapted for canine OSA)
Based on tumour grade, compartmental status, and presence of metastasis.
Prognostic Factors(6)
Minimum Workup(7 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.